ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ALNYLAM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$233.29+1.46 (+0.63%)
Close on Oct 19, 2026
- Market cap
- $32.26B
- P/E (TTM)
- 43.4
- Dividend yield
- –
ALNYLAM PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenues | $2.99B | $1.65B | $1.24B | $894.33M | $662.14M | $361.52M | $166.54M | $12.54M | $0 | 80.4% | +81.4% |
| Total TTR | $2.49B | $1.22B | $912.38M | – | – | – | – | – | – | 67.0% | +103.3% |
| AMVUTTRA | $2.31B | $970.45M | $557.84M | $93.80M | $0 | $0 | – | – | – | 62.3% | +138.4% |
| Collaborations | $553.37M | $510.22M | $546.19M | $134.91M | $180.95M | – | – | – | – | 14.9% | +8.5% |
| Total Rare | $499.92M | $422.92M | $329.09M | – | – | – | – | – | – | 13.5% | +18.2% |
| GIVLAARI | $308.49M | $255.87M | $219.25M | $173.14M | $127.82M | $55.11M | $150.00K | $0 | – | 8.3% | +20.6% |
| OXLUMO | $191.44M | $167.05M | $109.84M | $69.78M | $59.59M | $333.00K | $0 | – | – | 5.2% | +14.6% |
| Royalty revenue | $174.02M | $91.79M | $40.63M | $8.18M | $1.20M | $0 | $0 | – | – | 4.7% | +89.6% |
| ONPATTRO | $172.79M | $252.86M | $354.55M | $557.61M | $474.74M | $306.08M | $166.39M | $12.54M | – | 4.7% | -31.7% |
By region
From the segment and revenue-disaggregation notes of Alnylam Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.